Cancer Drug Sales Power Up Kelun-Biotech’s Profit Engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China image credit: Bamboo Works Key
Kelun-Biotech is making more money from selling cancer medicines directly to patients instead of just licensing them to other companies. When a company's main products earn money and get insurance approval, it shows their business plan is working—which is worth noticing when you follow the stock.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.